Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT06274554 Sponsor: Weill Medical College of Cornell University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT06274554
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old
  • You have been diagnosed with mild to moderate Crohn's disease, based on a specific scoring system called the CDAI (with a score between 150 and 450)

Who may not be able to join:

  • You have used antifungal medication in the month before the trial starts
  • You have a known allergy to the drug fluconazole
  • You have a known liver disease, liver scarring (cirrhosis), or abnormal liver test results at the start of the trial
  • You are currently taking medications that your doctor believes could dangerously interact with fluconazole, potentially causing serious problems such as heart issues or other severe reactions
  • You are pregnant or currently breastfeeding
  • You have severe Crohn's disease, may need surgery soon, or your doctor does not consider you medically well enough to participate
  • You have a narrowing or blockage in your digestive tract that is causing symptoms (confirm with trial site)
  • You have inflammation of an internal pouch (pouchitis) or have a stoma (an opening on the abdomen for waste)
  • You currently have an active fungal infection
  • You have low potassium levels in your blood or serious heart failure
  • You have kidney problems or reduced kidney function

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Randy Longman, MD, PhD, Weill Medical College of Cornell University

Phone: 646-697-0985

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
4 October 2024
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of subjects achieving clinical response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov